Please assess the completion status of the following clinical trial:

Trial Title: Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with stage IV, pathologically confirmed, NSCLC not suitable for/declining/not tolerating 1st/2nd-line palliative chemotherapy, or following completion of 1st/2nd-line palliative chemotherapy~* A likely prognosis of ≥3 months.~* Cachexia on the basis of any of the following, weight loss \>5% over past 6 months, or BMI \<20kg/m2 and weight loss \>2%, or appendicular skeletal muscle index determined by duel energy x-ray absorptiometry consistent with sarcopenia and weight loss \>2%.~* Systemic inflammation on the basis of a C-reactive protein \>10mg/L.~* Adequate renal function as defined by creatinine ≤132micromol/L and eGFR ≥30mL/min/1.73m2~* Adequate liver function as defined by the following parameters, bilirubin ≤25micromol/L, and AST and ALT ≤2 times upper limit of normal, unless liver metastases, in which case ≤5 times upper limit of normal~* Prepared to suspend, if necessary, the use of certain statins and/or substitute the use of domperidone for an alternative anti-emetic for the duration of the study~Exclusion Criteria:~* ECOG Performance Status 3 or 4~* Little or no food intake~* Weight loss \>10% in 1 month or \>20% in total~* Known hypersensitivity to clarithromycin~* Inability to accurately measure QT interval, e.g. atrial fibrillation~* QTc prolongation \>450 milliseconds in a male, or 470 milliseconds in a female~* History of ventricular arrhythmia~* Severe cardiac insufficiency (NYHA class \>2)~* Untreated hypokalaemia/hypomagnesaemia~* Active infection requiring antibiotics~* Current or recent (within last 4 weeks) history of Clostridium difficile, eating disorder, dysphagia, malabsorption or diarrhoea~* Untreated adrenal or thyroid diseases~* Brain metastases~* Use of corticosteroids/progestogens~* Use of chemotherapy, other immunosuppressive, or antiviral (e.g. hepatitis C, HIV) drugs within 4 weeks~* Drugs which are contra-indicated (except certain statins which can be temporarily suspended and domperidone which can be substituted for an alternative anti-emetic) or should be avoided in patients receiving clarithromycin, either because of the risk of a drug-drug interaction and/or prolonged QT~* Pregnancy~* Breast Feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clarithromycin (Type: ACTIVE_COMPARATOR): Clarithromycin 250mg by mouth twice a day for 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched capsule one capsule by mouth twice a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).